JP2021080270A - Composition comprising xanthophyll and processed trapaceae plant - Google Patents

Abstract

To provide a composition that is used for preventing and/or treating deterioration of visual functions and preventing and/or treating eye diseases.SOLUTION: The present disclosure provides a novel composition containing xanthophyll or a salt thereof and processed Trapaceae plants, and an ophthalmic composition containing processed Trapaceae plants. The xanthophyll is at least one selected from the group consisting of lutein, astaxanthin, β-cryptoxanthin, zeaxanthin, mesozeaxanthin, canthaxanthin, capsanthin and fucoxanthin.SELECTED DRAWING: Figure 1

Description

The present invention relates to 1) a novel composition containing xanthophyll or a salt thereof and a processed product of a Trapa plant, 2) a novel ophthalmic composition containing a processed product of a Trapa plant, and 3) lutein or a salt thereof. Relevant to new uses of ophthalmic compositions containing The composition of the present invention can be used for prevention and / or improvement of visual function deterioration and the like and prevention and / or treatment of eye diseases and the like.

With the widespread use of personal computers, the Internet, smartphones, etc., an increasing number of people are complaining of eye fatigue (eye strain) and associated systemic fatigue (eye strain). In addition, deterioration of visual function associated with aging and eye diseases such as presbyopia, cataract, glaucoma, age-related macular degeneration, and diabetic retinopathy is serious because it causes a significant decrease in QOL (Quality of Life). It has become a social problem. Therefore, the number of people who complain of troubles caused by eyes or eyes (eye strain, aging of eyes, various diseases caused by them) is increasing year by year, and the visual function is maintained to prevent troubles caused by eyes or eyes. There is also an increasing need for supplements that improve or medicines that treat eyes or eye problems.

In particular, presbyopia loses its elasticity due to aging of the crystalline lens (opacity (white turbidity), hardening, etc.) of the crystalline lens due to aging and extreme use of IT tools such as personal computers, the Internet, and smartphones for a long period of time. It is one of the typical troubles caused by eyes or eyes with subjective symptoms such as tired eyes, haze, and stiff shoulders due to impaired eye focus adjustment function.

Xanthophyll is a carotenoid-derived pigment, and compounds containing lutein, astaxanthin, zeaxanthin, mesozeaxanthin, and the like are known. In addition, since these xanthophylls cannot be biosynthesized in the human body, humans need to ingest xanthophylls from food or the like. Furthermore, xanthophyll is also known to improve accommodation dysfunction and eye strain of the eye (Patent Document 1).

Lutein is a type of carotenoid that is abundant in green and yellow vegetables, and is one of the major carotenoids in the body. Although lutein has an antioxidant effect, it is consumed by aging, ultraviolet rays, etc., so it is necessary to take it continuously through daily meals and supplements such as Santeltax (registered trademark) 20 (Non-Patent Document 1). Furthermore, it has been pointed out that lack of lutein in the body may cause various eye problems such as cataract, age-related macular degeneration, and dry eye.

Astaxanthin is a type of carotenoid that is abundant in salmon, salmon roe, crab, shrimp, red sea bream and the like. Astaxanthin is a pigment biosynthesized by Haematococcus algae, and this astaxanthin also has an antioxidant effect. In addition, astaxanthin is known to be useful for improving eye inflammatory diseases such as eyestrain and uveitis, and is incorporated into many supplements and cosmetics.

Zeaxanthin, like lutein, is a type of carotenoid, a fat-soluble substance similar to β-carotene, and a structural isomer of lutein. In addition, since zeaxanthin is abundant in the macula like lutein, it is said that zeaxanthin also has a function of protecting the macula like lutein.

Mesozeaxanthin is a metabolite of lutein and is a stereoisomer of zeaxanthin. In addition, mesozeaxanthin is said to have the same function as zeaxanthin.

It is known that an extract of a trapa genus plant obtained by hot water extraction of the peel of a trapa genus plant, particularly a trapa extract, is called a trapa extract and has a saccharification inhibitory effect (Patent Document 2). Advanced glycation end products (AGEs) produced by saccharification are also known to be involved in the development of various aging phenomena and diseases by causing denaturation and functional deterioration of biological proteins such as collagen and elastin. ing. By suppressing this saccharification action, it is expected to prevent the aging of the living body, particularly the aging of the skin. Therefore, the Tobishi extract is blended in cosmetics and the like.

Ultraviolet rays are invisible electromagnetic waves having a wavelength of 10 to 400 nm, those having a wavelength of less than 280 nm are called UV-C, those having a wavelength of 280 to 315 nm are called UV-B, and those having a wavelength of 315 to 400 nm are called UV-A. In addition, ultraviolet rays have useful effects such as sterilization and disinfection, synthesis of vitamin D in the body, blood circulation to the living body, and promotion of metabolism, but on the other hand, they induce skin cancer due to DNA damage, generate skin stains, and each tissue. It is also widely known that it causes accelerated aging and eye damage. It is also known that ultraviolet rays are emitted from IT tools such as personal computers, the Internet, and smartphones.

However, the use of xanthophylls or salts thereof in combination with processed products of Trapa plants, for example, compositions containing xanthophylls or salts thereof and processed products of Trapa plants, 1) cornea induced by ultraviolet irradiation, etc. It is not known to suppress the epithelial cell death of the trapa, 2) to suppress the opacity (white turbidity) of the crystalline lens of the diabetic model rat, and 3) to suppress or improve the damage to the retina of the diabetic model rat.

In addition, the use of a processed product of the genus Trapa alone, for example, a composition containing the processed product of the genus Trapa suppresses 1) suppression of epithelial cell death of the cornea and the like induced by ultraviolet irradiation, and 2) It is also not known to suppress the opacity (white turbidity) of the crystalline lens of the diabetic model rat, and 3) to suppress or improve the damage to the retina of the diabetic model rat.

Furthermore, it is not known that lutein or a salt thereof is used alone, and that a composition containing lutein or a salt thereof suppresses epithelial cell death such as cornea induced by ultraviolet irradiation.

Japanese Patent Application Laid-Open No. 2008-297222 JP-A-2014-94964

Sawa M, Gomi F, Hara C, Nishida K. Effects of a lutein supplement on the plasma lutein concentration and macular pigment in patients with central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2014 Jul 29; 55 (8): 5238-44. doi: 10.1167 / iovs.14-14470.

The problems to be solved by the present invention are 1) a novel composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa and its ophthalmic use, and 2) a new ophthalmic use containing a processed product of the genus Trapa. To provide new uses for compositions, as well as 3) ophthalmic compositions containing lutein or salts thereof.

By using a combination of lutein and Hishi extract, Hishi extract alone, or lutein alone, we can effectively suppress corneal epithelial cell death, suppress cloudiness (opacity) of the crystalline lens, and retina. It has been found to suppress or ameliorate damage. That is, a combination of xanthophyll or a salt thereof and a processed product of Trapa, a processed product of Trapa, or lutein or a salt thereof acts on the cornea, lens, retina, etc. constituting the eye to reduce visual function and the like. The present invention has been completed by finding prevention, treatment or amelioration of the accompanying subjective symptoms.

That is, the present invention relates to the following.
Item 1-1. A composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-2. Item 2. The composition according to Item 1-1, wherein the xanthophyll is at least one selected from the group consisting of lutein, astaxanthin, β-cryptoxanthin, zeaxanthin, mesozeaxanthin, canthaxanthin, capsanthin and fucoxanthin.
Item 1-3. Item 2. The composition according to Item 1-1 or 1-2, wherein the xanthophyll is at least one selected from the group consisting of lutein, astaxanthin, zeaxanthin and mesozeaxanthin.
Item 1-4. Any one of Items 1-1 to 1-3, wherein the processed product of Trapa japonica is a processed product of at least one Trapa plant selected from the group consisting of Trapa incisa, Trapa incisa, Trapa japonica, Trapa natans, and Trapa natans. The composition according to paragraph 1.
Item 1-5. Item 8. The composition according to any one of Items 1-1 to 1-4, wherein the processed product of the Trapa plant is a pulverized product or an extract of the pericarp of the Trapa plant.
Item 1-6. Item 2. The composition according to any one of Items 1-1 to 1-5, wherein the processed product of the genus Trapa contains 0.1 to 80% by weight of polyphenol based on the total weight of the processed product of the genus Trapa. Stuff.
Item 1-7. A composition containing lutein or a salt thereof and a processed product of Tobishi.
Item 1-8. Item 2. The composition according to Item 1-7, wherein the processed product of Tobishi is a pulverized product and / or extract of the peel of Tobishi.
Item 1-9. Item 2. The composition according to Item 1-7 or 1-8, wherein the processed Tobishi product contains 0.1 to 80% by weight of polyphenol based on the total weight of the processed Tobishi product.
Item 1-10. Item 8. The composition according to any one of Items 1-1 to 1-9, wherein the composition is for oral or parenteral use.
Item 1-11. Item 2. The composition according to any one of Items 1-1 to 1-10, wherein the composition is for food or drink or pharmaceutical use.
Item 1-12. Item 8. The composition according to any one of Items 1-1 to 1-11, wherein the composition is for supplements.
Item 1-13. Item 2. The composition according to any one of Items 1-1 to 1-12, wherein the composition is for ophthalmology.
Item 1-14. Item 2. The composition according to any one of Items 1-1 to 1-13, wherein the composition is a soft capsule, a hard capsule, a liquid preparation, a jelly, a gummies, a tablet or a powder.
Item 1-15. Item 8. The composition according to any one of Items 1-1 to 1-14, for preventing and / or ameliorating visual dysfunction and associated subjective symptoms.
Item 1-16. Item 2. The composition according to Item 1-15, wherein the decrease in visual function is eye fatigue, aging of the eye, or decrease in the ability to adjust the focus of the eye.
Item 1-17. Item 12. The composition according to Item 1-15 or 1-16, wherein the visual dysfunction is a visual dysfunction induced by aging, ultraviolet rays, poor circulation, dryness, active oxygen and / or inflammation.
Item 1-18. Item 2. The composition according to Item 1-15, wherein the subjective symptom is stiff shoulders, nape of the neck, back or lower back.
Item 1-19. Item 2. The composition according to Item 1-1 to 1-14, for the prevention and / or treatment of eye diseases.
Item 1-20. Item 2. The composition according to Item 1-19, wherein the eye disease is an eye disease induced by aging, ultraviolet rays, poor circulation, dryness, active oxygen and / or inflammation.
Item 1-21. Eye diseases include eye strain, cataract, age-related luteal degeneration, diabetic retinopathy, retinitis pigmentosa, central serous chorioretinopathy, glaucoma, vegetation inflammation, presbyopia, myopia, dry eye, pterygium and inflammatory Item 2. The composition according to Item 1-19 or 1-20, which is selected from the group consisting of eye diseases.
Item 1-22. Item 8. The composition according to any one of Items 1-1 to 1-14, for the prevention, amelioration and / or treatment of corneal disorders.
Item 1-23. Item 2. The composition according to Item 1-22, wherein the corneal disorder is an ultraviolet-induced corneal disorder.
Item 1-24. Item 8. The composition according to any one of Items 1-1 to 1-14, for preventing, ameliorating and / or treating lens degeneration.
Item 1-25. Item 2. The composition according to Item 1-24, wherein the lens denaturation is opacity or hardening of the lens.
Item 1-26. Item 8. The composition according to any one of Items 1-1 to 1-14, for preventing, ameliorating and / or treating a decrease in accommodation function.
Item 1-27. Item 2. The composition according to Item 1-26, wherein the eye accommodation function is an accommodation accommodation function.
Item 1-28. Item 8. The composition according to any one of Items 1-1 to 1-14, for preventing, ameliorating and / or treating retinochoroidal disorders.
Item 1-29. The composition according to Item 1-28, wherein the retinal choroidal disorder is retinal damage.
Item 1-30. An agent for preventing and / or ameliorating visual dysfunction and associated subjective symptoms, which is characterized by combining xanthophyll or a salt thereof with a processed product of the genus Trapa.
Item 1-31. A prophylactic and / or therapeutic agent for eye diseases, which comprises combining xanthophyll or a salt thereof with a processed product of the genus Trapa.
Item 1-32. A prophylactic, ameliorating and / or therapeutic agent for corneal disorders, which comprises combining xanthophyll or a salt thereof with a processed product of the genus Trapa.
Item 1-33. Item 3. The composition according to Item 1-32, wherein the corneal disorder is UV-induced corneal damage.
Item 1-34. A prophylactic, ameliorating and / or therapeutic agent for lens degeneration, which comprises combining xanthophyll or a salt thereof with a processed product of the genus Trapa.
Item 1-35. The prophylactic, ameliorating and / or therapeutic agent according to Item 1-34, wherein the lens degeneration is opacity or hardening of the lens.
Item 1-36. A prophylactic, ameliorating and / or therapeutic agent for the deterioration of accommodation function, which is characterized by combining xanthophyll or a salt thereof with a processed product of the genus Trapa.
Item 1-37. Item 3. The prophylactic, ameliorating and / or therapeutic agent according to Item 1-36, wherein the accommodation function is an accommodation function.
Item 1-38. A prophylactic, ameliorating and / or therapeutic agent for retinal disorders, which comprises combining xanthophyll or a salt thereof with a processed product of the genus Trapa.
Item 1-39. The prophylactic, ameliorating and / or therapeutic agent according to Item 1-38, wherein the retinal disorder is retinal damage.
The invention in which items 1-1 to 1-39 are appropriately selected and combined is also within the scope of the present invention.

The present invention also relates to the following.
Item 1-40. Use of a composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa for the prevention and / or improvement of visual dysfunction and associated subjective symptoms.
Item 1-41. A method for preventing, ameliorating and / or treating visual dysfunction and associated subjective symptoms, which comprises administering an effective amount of xanthophyll or a salt thereof and a processed product of a Trapa plant.
Item 1-42. Use of a composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa, for the prevention and / or treatment of eye diseases.
Item 1-43. A method of preventing, ameliorating and / or treating an eye disease, which comprises administering an effective amount of xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-44. A Maillard reaction inhibitor containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-45. An antioxidant containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-46. An active oxygen scavenger containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-47. A phototoxicity inhibitor containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-48. Item 4. The phototoxicity inhibitor according to Item 1-47, wherein the light is ultraviolet light.
Item 1-49. An epithelial cell death inhibitor containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-50. Item 4. The epithelial cell death inhibitor according to Item 1-49, wherein the epithelial cells are corneal epithelial cells.
Item 1-51. A lens denaturation inhibitor containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-52. Item 5. The lens degeneration inhibitor according to Item 1-51, wherein the lens degeneration is opacity or hardening of the lens.
Item 1-53. An anti-aging agent containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-54. An anti-inflammatory agent containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-55. A reticulochoroidal damage inhibitor containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-56. Item 3. The agent for suppressing damage to the retina choroid according to Item 1-55, wherein the retina is the retina.
The invention in which items 1-1 to 1-56 are appropriately selected and combined is also within the scope of the present invention.

In addition, another aspect of the present invention relates to the following.
Item 2-1. An ophthalmic composition containing a processed product of the genus Trapa.
Item 2-2. Item 2. The ophthalmic composition according to Item 2-1. The processed product of Trapa japonica is a processed product of at least one Trapa japonica plant selected from the group consisting of Trapa japonica, Trapa japonica, Trapa japonica, Trapa natans and Trapa natans chinensis.
Item 2-3. Item 2. The ophthalmic composition according to any one of Items 2-1 or 2-2, wherein the processed product of the Trapa plant is a pulverized product or an extract of the pericarp of the Trapa plant.
Item 2-4. Item 2. Ophthalmology according to any one of Items 2-1 to 2-3, wherein the processed product of the genus Trapa contains 0.1 to 80% by weight of polyphenol based on the total weight of the processed product of the genus Trapa. Composition for.
Item 2-5. An ophthalmic composition containing a processed Tobishi product.
Item 2-6. Item 2. The ophthalmic composition according to Item 2-5, wherein the processed product of Tobishi is a pulverized product and / or extract of the peel of Tobishi.
Item 2-7. Item 2. The ophthalmic composition according to Item 2-5 or 2-6, wherein the processed Tobishi product contains 0.1 to 80% by weight of polyphenol based on the total weight of the processed Tobishi product.
Item 2-8. Item 2. The ophthalmic composition according to any one of Items 2-1 to 2-7, wherein the ophthalmic composition is oral or parenteral.
Item 2-9. Item 2. The ophthalmic composition according to any one of Items 2-1 to 2-8, wherein the ophthalmic composition is for food and drink or pharmaceuticals.
Item 2-10. Item 2. The ophthalmic composition according to any one of Items 2-1 to 2-9, wherein the ophthalmic composition is for a supplement.
Item 2-11. Item 2. The ophthalmic composition according to any one of Items 2-1 to 2-10, wherein the ophthalmic composition is a soft capsule, a hard capsule, a liquid preparation, a jelly, a gummies, a tablet or a powder.
Item 2-12. Item 8. The ophthalmic composition according to any one of Items 2-1 to 2-11, for preventing and / or ameliorating visual dysfunction and associated subjective symptoms.
Item 2-13. Item 2. The composition according to Item 2-12, wherein the deterioration of visual function is eye fatigue, aging of the eye, or deterioration of the accommodation function of the eye.
Item 2-14. Item 2. The composition according to Item 2-12 or 2-13, wherein the visual dysfunction is a visual dysfunction induced by aging, ultraviolet rays, poor circulation, dryness, active oxygen and / or inflammation.
Item 2-15. Item 2. The composition according to Item 2-12, wherein the subjective symptom is stiff shoulders, nape of the neck, back or lower back.
Item 2-16. Item 2. The ophthalmic composition according to Item 2-1 to Item 2-11 for prevention and / or treatment of eye diseases.
Item 2-17. Item 2. The ophthalmic composition according to Item 2-16, wherein the eye disease is induced by aging, ultraviolet rays, poor circulation, dryness, active oxygen and / or inflammation.
Item 2-18. Eye diseases include eye strain, cataracts, age-related luteal degeneration, diabetic retinopathy, retinitis pigmentosa, central serous chorioretinopathy, glaucoma, glaucoma, presbyopia, myopia, dry eyes, pterygium and inflammation. Item 2. The ophthalmic composition according to Item 2-16 or 2-17, which is selected from the group consisting of glaucoma.
Item 2-19. Item 8. The ophthalmic composition according to any one of Items 2-1 to 2-11, for the prevention, amelioration and / or treatment of corneal disorders.
Item 2-20. Item 2. The ophthalmic composition according to Item 2-19, wherein the corneal disorder is an ultraviolet-induced corneal disorder.
Item 2-21. Item 8. The ophthalmic composition according to any one of Items 2-1 to 2-10, for preventing, ameliorating and / or treating lens degeneration.
Item 2-22. Item 2. The ophthalmic composition according to Item 2-21, wherein the lens degeneration is opacity or hardening of the lens.
Item 2-23. Item 8. The ophthalmic composition according to any one of Items 2-1 to 2-11, for preventing, ameliorating and / or treating a decrease in accommodation function.
Item 2-24. Item 2. The ophthalmic composition according to Item 2-23, wherein the accommodation function is an accommodation function.
Item 2-25. Item 8. The ophthalmic composition according to any one of Items 2-1 to 2-11, for preventing, ameliorating and / or treating retinochoroidal disorders.
Item 2-26. Item 2. The ophthalmic composition according to Item 2-25, wherein the retinal choroidal disorder is retinal damage.
Item 2-27. A preventive and / or ameliorating agent for visual dysfunction and associated subjective symptoms containing a processed product of the genus Trapa.
Item 2-28. A preventive and / or therapeutic agent for eye diseases containing a processed product of the genus Trapa.
Item 2-29. A preventive, ameliorating and / or therapeutic agent for corneal disorders containing a processed product of the genus Trapa.
Item 2-30. The prophylactic, ameliorating and / or therapeutic agent according to Item 2-29, wherein the corneal disorder is an ultraviolet-induced corneal disorder.
Item 2-31. A prophylactic, ameliorating and / or therapeutic agent for lens degeneration containing a processed product of the genus Trapa.
Item 2-32. Item 2. The preventive, ameliorating and / or therapeutic agent according to Item 2-31, wherein the lens degeneration is opacity or hardening of the lens.
Item 2-33. A prophylactic, ameliorating and / or therapeutic agent for a decrease in accommodation function containing a processed product of the genus Trapa.
Item 2-34. Item 2. The prophylactic, ameliorating and / or therapeutic agent according to Item 2-33, wherein the accommodation function is an accommodation function.
Item 2-35. A prophylactic, ameliorating and / or therapeutic agent for reticulochoroidal disorders containing a processed product of the genus Trapa.
Item 2-36. The prophylactic, ameliorating and / or therapeutic agent according to Item 2-35, wherein the retinal choroidal disorder is retinal damage.
The invention in which items 2-1 to 2-36 are appropriately selected and combined is also within the scope of the present invention.

The present invention also relates to the following.
Item 2-37. Use of an ophthalmic composition containing a processed product of the genus Trapa for the prevention and / or amelioration of visual dysfunction and associated subjective symptoms.
Item 2-38. A method for preventing, ameliorating and / or treating visual dysfunction and associated subjective symptoms, which comprises administering an effective amount of a processed product of the genus Trapa.
Item 2-39. Use of an ophthalmic composition containing a processed product of the genus Trapa for the prevention and / or treatment of eye diseases.
Item 2-40. A method of preventing, ameliorating and / or treating an eye disease, which comprises administering an effective amount of a processed product of the genus Trapa.
Item 2-41. A Maillard reaction inhibitor in the eye containing a processed product of the genus Trapa.
Item 2-42. Antioxidants in the eye containing processed products of the genus Trapa.
Item 2-43. An active oxygen scavenger in the eye containing a processed product of the genus Trapa.
Item 2-44. A phototoxicity inhibitor in the eye containing a processed product of the genus Trapa.
Item 2-45. Item 2. The phototoxicity inhibitor according to Item 2-44, wherein the light is ultraviolet light.
Item 2-46. An epithelial cell death inhibitor containing a processed product of the genus Trapa.
Item 2-47. Item 2. The epithelial cell death inhibitor according to Item 2-46, wherein the epithelial cells are corneal epithelial cells.
Item 2-48. A lens denaturation inhibitor containing a processed product of the genus Trapa.
Item 2-49. Item 2. The lens degeneration inhibitor according to Item 2-48, wherein the lens degeneration is opacity or hardening of the lens.
Item 2-50. An anti-aging agent in the eye containing a processed product of the genus Trapa.
Item 2-51. An eye inflammation improving agent containing a processed product of the genus Trapa.
Item 2-52. An agent for suppressing damage to the reticulochoroid containing a processed product of the genus Trapa.
Item 2-53. Item 2. The agent for suppressing damage to the retina choroid according to Item 2-52, wherein the retina is the retina.
The invention in which items 2-1 to 2-53 are appropriately selected and combined is also within the scope of the present invention.

Furthermore, another aspect of the present invention relates to the following.
Item 3-1. A corneal epithelial cell death inhibitor containing lutein or a salt thereof.
Item 3-2. Item 3. The corneal epithelial cell death inhibitor according to Item 3-1 which is UV-induced corneal epithelial cell death.
Item 3-3. Item 3. The corneal epithelial cell death inhibitor according to Item 3-1 or 3-2, wherein the ultraviolet rays are UV-B.
Item 3-4. An ophthalmic composition containing lutein or a salt thereof for preventing and / or ameliorating ultraviolet-induced visual dysfunction and associated subjective symptoms.
Item 3-5. An ophthalmic composition containing lutein or a salt thereof for the prevention and / or treatment of ultraviolet-induced eye diseases.
Item 3-6. An ophthalmic composition containing lutein or a salt thereof for the prevention and / or treatment of ultraviolet-induced corneal disorders.
Item 3-7. Item 3. The ophthalmic composition according to Item 3-4 to 3-6, wherein the ophthalmic composition is oral or parenteral.
Item 3-8. Item 3. The ophthalmic composition according to Item 3-4 to 3-7, wherein the ophthalmic composition is for food or drink or medicine.
Item 3-9. Item 8. The ophthalmic composition according to any one of Items 3-4 to 3-8, wherein the ophthalmic composition is for a supplement.
Item 3-10. Item 8. The ophthalmic composition according to any one of Items 3-4 to 3-9, wherein the ophthalmic composition is a soft capsule, a hard capsule, a liquid preparation, a jelly, a gummies, a tablet or a powder.
Item 3-11. Item 3. The ophthalmic composition according to Item 3-4, wherein the deterioration of visual function is eye fatigue, aging of the eye, or deterioration of the accommodation function of the eye.
Item 3-12. Item 3. The ophthalmic composition according to Item 3-4, wherein the subjective symptom is stiff shoulder, nape, back or lower back.
Item 3-13. Item 3. The ophthalmic composition according to Item 3-5, for the prevention and / or treatment of eye diseases.
Item 3-14. Item 2. Ophthalmology according to Item 3-5, wherein the eye disease is selected from the group consisting of eyestrain, cataract, age-related yellow spot degeneration, uveitis, presbyopia, myopia, dry eye, pterygium and inflammatory eye disease. Composition for.
Item 3-15. Item 3. The ophthalmic composition according to Item 3-6, wherein the corneal disorder is a corneal epithelial cell disorder.
The invention in which items 3-1 to 3-15 are appropriately selected and combined is also within the scope of the present invention.

Item 3-16. Use of an ophthalmic composition containing lutein or a salt thereof for the prevention and / or amelioration of ultraviolet-induced visual dysfunction and associated subjective symptoms.
Item 3-17. A method for preventing and / or ameliorating UV-induced visual dysfunction and associated subjective symptoms, which comprises administering an effective amount of lutein or a salt thereof.
Item 3-18. Use of an ophthalmic composition containing lutein or a salt thereof for the prevention and / or treatment of UV-induced eye diseases.
Item 3-19. A method of preventing and / or ameliorating UV-induced eye disease, which comprises administering an effective amount of lutein or a salt thereof.
The invention in which items 3-1 to 3-19 are appropriately selected and combined is also within the scope of the present invention.

The present invention provides a composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa. Further, the present invention provides ophthalmic uses of a composition containing xanthophyll or a salt thereof and a processed product of a Trapa plant, in particular, prevention and / or improvement of visual function deterioration and prevention and / or therapeutic use of eye diseases and the like.

A composition containing xanthophile or a salt thereof and a processed product of the genus Hishi effectively suppresses corneal epithelial cell death induced by ultraviolet irradiation, and thus is caused by ultraviolet rays (due to DNA damage caused by ultraviolet rays). Prevention and / or improvement of functional deterioration (eye fatigue, eye aging, etc.) and associated subjective symptoms (stiffness of shoulders, neck muscles, back, hips, etc.) and eye diseases (eye strain, cataracts, age-related pterygium degeneration, inflammation, etc.) It is expected to be useful for the prevention or treatment of sexual eye diseases, pterygium, etc.).
At the same time, since it effectively suppresses the death of living cells caused by ultraviolet rays, it is also useful for prevention, improvement and / or treatment of induction of skin cancer, formation of skin stains, acceleration of aging of each tissue, and the like. It is also expected.

In addition, since the composition containing xanthophile or a salt thereof and a processed product of the genus Hishi effectively suppresses the white turbidity of the crystalline lens, the opacity of the crystalline lens (white turbidity), that is, the deterioration of visual function due to the degeneration of the crystalline lens. Prevention and / or improvement of (eye fatigue, presbyopia, deterioration of eye focus adjustment function, etc.) and associated subjective symptoms (stiffness of shoulders, neck muscles, back, hips, etc.) and eye diseases (eye fatigue, cataracts, etc.) It is expected to be useful for the prevention or treatment of presbyopia, etc.). In particular, degeneration of the crystalline lens greatly affects the focus adjustment function of the eye, and is therefore expected to be particularly effective in the prevention, improvement and / or treatment of presbyopia, myopia and the like, which are diseases related to the focus adjustment function.

Furthermore, compositions containing xanthophile or salts thereof and processed products of the genus Hishi effectively suppress or ameliorate damage to the retinopathy, and thus impair visual function (eye strain, eye fatigue) accompanied by damage to the retinochoroid. Prevention and / or improvement of (aging, etc.) and associated subjective symptoms (stiffness of shoulders, neck muscles, back, hips, etc.) and eye diseases (eye strain, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, central serous chorioret) It is expected to be effective in the prevention or treatment of retinitis chorioretopathy, glaucoma, uveitis and other retinous choroidal diseases).

The present invention provides an ophthalmic composition containing a processed product of the genus Trapa. Further, the processed product of the genus Trapa is provided for ophthalmic use, particularly for prevention and / or improvement of visual function deterioration and prevention and / or treatment of eye diseases and the like.

Compositions containing processed products of the genus Hishi effectively suppress corneal epithelial cell death induced by UV irradiation, resulting in decreased visual function (eye strain, eye aging, etc.) and eye aging caused by UV light. Prevention and / or improvement of subjective symptoms (stiffness of shoulders, neck muscles, back, hips, etc.) and prevention or treatment of eye diseases (eye strain, cataracts, age-related yellow spot degeneration, inflammatory eye diseases, pterygium, etc.) It is expected to be useful for.

In addition, since the composition containing the processed product of the genus Hishi effectively suppresses the white turbidity of the crystalline lens, the opacity of the crystalline lens (white turbidity), that is, the deterioration of visual function due to the degeneration of the crystalline lens (eye fatigue, Prevention and / or improvement of eye aging, deterioration of eye focus adjustment function, etc.) and associated subjective symptoms (stiffness of shoulder, neck muscle, back, waist, etc.) and eye diseases (eye fatigue, cataract, presbyopia, etc.) It is expected to be useful for prevention or treatment. In particular, degeneration of the crystalline lens greatly affects the focus adjustment function of the eye, and is therefore expected to be particularly effective in the prevention, improvement and / or treatment of presbyopia, myopia and the like, which are diseases related to the focus adjustment function.

In addition, compositions containing processed products of the genus Hishi effectively suppress or ameliorate retinal damage, resulting in visual deterioration (eye strain, eye aging, etc.) associated with glaucoma damage and the like. Prevention and / or improvement of accompanying subjective symptoms (stiffness of shoulders, neck muscles, back, hips, etc.) and eye diseases (eye strain, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, central serous chorioretinopathy, It is expected to be effective in the prevention or treatment of glaucoma, retinopathy such as uveitis).

The present invention provides a corneal epithelial cell death inhibitor containing lutein or a salt thereof. In particular, it provides an agent for suppressing corneal epithelial cell death induced by ultraviolet rays.

It is a graph which shows the cell viability of the corneal epithelial cell when the corneal epithelial cell is treated with lutein, Hishi extract before UV-B irradiation (120 mJ / cm ^2). It is a graph which shows the effect on the opacity (white turbidity) of a crystalline lens. It is a graph which shows the effect on the damage of the retina.

Hereinafter, the present invention will be described in detail.

One aspect of the present invention is a composition containing xanthophyll or a salt thereof and a processed product of a Trapa plant.

In the present invention, xanthophyll is not particularly limited. Specific examples of xanthophylls include lutein, astaxanthin, zeaxanthin, mesozeaxanthin, β-cryptoxanthin, tunaxanthin, salmoxanthin, parasiloxanetin, violaxanthin, anteraxanthin, kukurubitaxanthin, diatoxanthin, alloxanthin, pectenol, pectenolone. , Mactraxanthin, Capsantin, Capsantinol, Fucoxanthin, Fucoxanthinol, Peridinin, Halosinthiaxanthin, Amarousiaxanthin, Canthaxanthin, Equinenone, Rodoxanthin, Bixin, Norbicin and the like. Preferred examples include lutein, astaxanthin, β-cryptoxanthin, zeaxanthin, mesozeaxanthin, canthaxanthin, capsanthin or fucoxanthin, and particularly preferably lutein, astaxanthin, zeaxanthin or mesozeaxanthin. The xanthophyll is derived from natural substances such as plants, animals, and microorganisms (for example, plants such as marigold, spinach, and kale, animal fat, egg yolk, macula, crustacean shell, and crustacean shell as food. It may be obtained from the body surface of a crustacean, the red part of the muscle of a crustacean, the retina of the eye, the macula, etc.), or it may be chemically synthesized (manufactured by a general synthetic method). ) May be. Further, those derived from natural products are not particularly limited depending on the type of raw material, the place of production, the manufacturing method and the like.

あり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, lutein is (3R, 3'R, 6'R) -β, ε-carotene-3,3'-diol:

Yes, including its stereoisomers, as well as their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, astaxanthin is (3S, 3'S) -3,3'-dihydroxy-β, β-carotene-4,4'-dione:

And include its stereoisomers and their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, β-cryptoxanthin is (3R) -β, β-carotene-3-ol:

And include its stereoisomers and their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, zeaxanthin is a (3R, 3'R) -β, β-carotene-3,3'-diol:

And include its stereoisomers and their monoesters and / or diesters.

あり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, mesozeaxanthin is a (3R, 3'S) -β, β-carotene-3,3'-diol:

Yes, including its stereoisomers, as well as their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, canthaxanthin is β, β-carotene-4,4'-dione:

And include its stereoisomers and their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, capsanthin is (3R, 3'S) -3,3'-dihydroxy-β, κ-carotene-6'-on:

And include its stereoisomers and their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, fucoxanthin is (3S, 3'S, 5R, 5'R, 6S, 6'R) -3'-acetoxy-6', 7'-didehydro-5,6-epoxy-5,5. ′, 6,6 ′, 7,8-Hexahydro-3,5′-dihydroxy-8-oxo-β, β-carotene:

And include its stereoisomers and their monoesters and / or diesters.

In the present invention, xanthophylls include xanthophylls and / or esters thereof, unless otherwise specified. In addition, xanthophyll esters include monoesters and / or diesters.

In the present invention, examples of the monoester of xanthophile include esters esterified with lower or higher saturated fatty acids or lower or higher unsaturated fatty acids. Specific examples of the lower or higher saturated fatty acids or lower or higher unsaturated fatty acids include acetic acid, lauric acid, myristic acid, capric acid, pentadecanoic acid, palmitic acid, palmitooleic acid, hebutadecanoic acid, ellaidic acid and ricinol. Acids, betroceric acid, baccenoic acid, eleostearic acid, punicinic acid, licanoic acid, parinaric acid, gadoric acid, 5-eicosenoic acid, 5-dococenoic acid, cetolic acid, erucic acid, 5,13-docosadienoic acid, ceracolic acid , Decenoic acid, dodecenoic acid, oleic acid, stearic acid, eikosaopentaenoic acid, docosahexaenoic acid, linoleic acid, linolenic acid, arachidonic acid and the like.

In the present invention, as further monoesters of xanthophile, for example, fatty acids such as glycine and alanine; monovalent or polyvalent carboxylic acids such as acetic acid and citric acid; inorganic acids such as phosphoric acid and sulfuric acid; sugars such as glucoside. Examples thereof include sugar fatty acids such as glycerosaccharide fatty acids and spingosaccharide fatty acids; fatty acids such as glycero fatty acids; and monoesters esterified with glycerophosphate and the like. When a salt can be assumed as the monoester, the salt of the monoester is also included. Here, examples of the fatty acid derivative include a phospholipid type, an alcohol type, an ether type, a sucrose ester type, and a polyglycerin ester type of the fatty acid.

In the present invention, the diester form of xanthophile includes, for example, the lower saturated fatty acid, higher saturated fatty acid, lower unsaturated fatty acid, higher unsaturated fatty acid, amino acid, monovalent or polyvalent carboxylic acid, inorganic acid, sugar, sugar fatty acid, fatty acid. And diesters esterified with the same or different acids selected from the group consisting of glycerophosphate. When a salt can be assumed as the diester, the salt of the diester is also included. Here, examples of the diester of glycerophosphate include saturated fatty acid esters of glycerophosphate or glycerophosphates containing fatty acids selected from higher unsaturated fatty acids, unsaturated fatty acids and saturated fatty acids.

In the present invention, the salt of xanthophyll is not particularly limited as long as it is a physiologically or pharmaceutically acceptable salt. For example, salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitrate, sulfuric acid, phosphoric acid; acetic acid, fumaric acid, maleic acid, succinic acid, citric acid, tartrate acid, adipic acid, gluconic acid, Glucoheptoic acid, glucuronic acid, terephthalic acid, methanesulfonic acid, lactic acid, horseuric acid, 1,2-ethanedisulfonic acid, isetionic acid, lactobionic acid, oleic acid, pamoic acid, polygalacturonic acid, stearic acid, tannic acid, trifluoromethane Salts with organic acids such as sulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, lauryl ester sulfate, methyl sulfate, naphthalenesulfonic acid, sulfosalicylic acid; quaternary ammonium salt with methyl bromide, methyl iodide, etc .; bromine Salts with halogen ions such as ions, chlorine ions and iodine ions; Salts with alkali metals such as lithium, sodium and potassium; Salts with alkaline earth metals such as calcium and magnesium; Metal salts with iron, zinc and the like; Salt with ammonia; triethylenediamine, 2-aminoethanol, 2,2-iminobis (ethanol), 1-deoxy-1- (methylamino) -2-D-sorbitol, 2-amino-2- (hydroxymethyl)- Examples thereof include salts with organic amines such as 1,3-propanediol, procaine, N, N-bis (phenylmethyl) -1,2-ethanediamine and the like.

In the present invention, the lower limit of xanthophyll or a salt thereof is 0.1% by weight, preferably 0.5% by weight, more preferably 1% by weight, still more preferably 1. It is 5% by weight, particularly preferably 2% by weight. The upper limit thereof is 90% by weight, preferably 80% by weight, more preferably 70% by weight, still more preferably 60% by weight, and particularly preferably 50% by weight. Further, the upper limit and the lower limit thereof can be used in combination as appropriate. More specifically, for example, 0.1 to 90% by weight, preferably 0.5 to 80% by weight, more preferably 0.1 to 70% by weight, still more preferably 1.5 to 60% by weight, particularly preferably. Can be used in 2 to 50% by weight.

In the present invention, the Trapa plant is not particularly limited. Specific examples of the water chestnut genus (Trapa) plants, Tsunonashibishi (Trapa acornis Nakano), Himebishi (Trapa incisa Sieb. Et Zuc.), Water chestnut (Trapa japonica Flerov), Toubishi (Trapa bispinosa Roxb.), Torapa-Natansu (Trapa natans L.), Onibishi (Trapa natans L. var. Japanica Nakai) and the like, preferably Hishi (Trapa japonica Flelov), Tobishi (Trapa bispinosa Roxb.), Onibishi (Tr). In particular, trapa trapa (Trapa bispinosa Roxb.) Can be mentioned.

In the present invention, a processed product of a Trapa plant can be prepared and produced from the whole or each part of the Trapa plant. Examples of each part include flowers, spikes, pericarp, fruits, flesh, stems, leaves, branches, branches and leaves, trunks, bark, rhizomes, root bark, roots, seeds, insects, heartwood, above-ground parts, or underground parts. The peel is particularly preferable. The method for preparing and producing a processed product of the genus Trapa is not particularly limited, and for example, it can be prepared and produced by a commonly used method.

In the present invention, the lower limit of the content of polyphenols based on the total weight of the processed products of Trapa plants is 0.1% by weight, preferably 5% by weight, and particularly preferably 10% by weight. The upper limit is 80% by weight, preferably 70% by weight, and particularly preferably 60% by weight. Further, the upper limit and the lower limit thereof can be used in combination as appropriate. More specifically, the content of polyphenols based on the total weight of the processed products of the genus Trapa is 0.1 to 80% by weight, preferably 5 to 70% by weight, and particularly preferably 10 to 60% by weight. Moreover, the polyphenol content can be measured by, for example, the FOLIN-CIOCALTEU method or the like.

In the present invention, the processed product of the Trapa plant is, for example, a pulverized product, an extract of the Trapa plant, and a dried product thereof. The crushed products, extracts and dried products of Trapa plants have, for example, roots, stems, leaves, flower buds, flowers, bark, fruits (seed), fruit skins, etc. of the Trapa plants as they are or of appropriate size. It can be prepared and manufactured by cutting, crushing, squeezing, extracting a solvent, etc., and in some cases, drying them. Further, it is also possible to prepare and produce by mixing each part of one or more kinds of Trapa plants.

In the present invention, for the preparation and production of the extract of the genus Trapa, for example, water, an organic solvent or a mixed solvent thereof can be used as the extraction solvent. Examples of the organic solvent include lower alcohols such as methanol and ethanol, chloroform, ethyl acetate, n-hexane and the like, and preferred examples include methanol and ethanol. In addition, two or more of these organic solvents can be mixed and used.

In the present invention, the amount of the extraction solvent used can be appropriately selected depending on the type and site of the Trapa plant, the type of the extraction solvent, and the like. The weight ratio of the Trapa plant to the extraction solvent is, for example, 1: 2 to 1:30, preferably 1: 3 to 1:20, and particularly preferably 1: 5 to 1:10. The extraction time is, for example, several minutes to 30 days, preferably 1 hour to 15 days. The extraction temperature is, for example, 5 to 100 ° C. The extraction method is not particularly limited, and any method such as batch extraction and continuous extraction using column extraction can be applied.

In the present invention, the obtained extract of the genus Trapa can be used as it is. Further, if necessary, further purification treatment can be added. This purification treatment may be carried out by a usual method, and for example, it can be purified by filtering an extract of a Trapa plant by a conventional method. Then, the obtained filtrate can be concentrated under reduced pressure, freeze-dried, or the like to obtain an extract of the Trapa plant according to the present invention.

In the present invention, as a processed product of the Trapa plant, for example, an extract of the pericarp of the Trapa plant or a dried product thereof can be used. The extract of the fruit skin of the Trapa genus plant or a dried product thereof is obtained by, for example, extracting the fruit skin of the Trapa genus plant with water or a lower alcohol such as methanol or ethanol, filtering and concentrating it, and optionally adding an excipient or the like. It can be prepared and manufactured by drying.

In the present invention, a particularly preferable processed product of the genus Trapa is a trapa extract, which is a processed product of Trapa.

In the present invention, the lower limit of the content of polyphenols based on the total weight of the extract of the peel of a plant of the genus Trapa is 0.1% by weight, preferably 1% by weight, more preferably 5% by weight, still more preferably 10% by weight, particularly. 20% by weight. The upper limit is 90% by weight, preferably 80% by weight, more preferably 70% by weight, still more preferably 65% by weight, and particularly preferably 60% by weight. Further, the upper limit and the lower limit thereof can be used in combination as appropriate. More specifically, the content of polyphenols based on the total weight of the extract of the peel of a plant of the genus Trapa is 0.1 to 90% by weight, preferably 1 to 80% by weight, more preferably 5 to 70% by weight, still more preferably. Is 10 to 65% by weight, particularly preferably 20 to 60% by weight.

In the present invention, examples of excipients added to the processed products of Trapa plants include dextrin, cyclodextrin, lactose, crystalline cellulose, silicon dioxide, cyclic oligosaccharides and the like, and cyclodextrin and cyclic oligosaccharides are preferable. Included, with particular preference being cyclodextrin.

In the present invention, the lower limit of the processed product of the genus Hishi is 0.1% by weight, preferably 1% by weight, more preferably 10% by weight, still more preferably 25% by weight, based on the total amount of the composition of the present invention. %, Especially 60% by weight, and the upper limit thereof is 99% by weight, preferably 95% by weight, more preferably 90% by weight, still more preferably 85% by weight, and particularly preferably 80% by weight. Further, the upper limit and the lower limit thereof can be used in combination as appropriate.
More specifically, it is used in an amount of 0.1 to 99% by weight, preferably 1 to 95% by weight, more preferably 10 to 90% by weight, still more preferably 25 to 85% by weight, and particularly preferably 60 to 80% by weight. can do.

In the present invention, other active ingredients (for example, substances having an auxiliary effect) can be further added in addition to xanthophylls and / or processed products of Trapa plants. For example, vitamin A; carotenoids (excluding xanthophile); vitamin B; vitamin C; vitamin D, vitamin E; tocotrienol; glutathione and its derivatives and salts thereof; catechin, anthocyanin, tannin, rutin, Polyphenols such as isoflavone, chlorogenic acid, ellagic acid, curcumin, coumarin; linoleic acid, α- or γ-linolenic acid, arachidonic acid, eicosapentaenoic acid, sardine acid, docosahexaenoic acid and its derivatives and salts thereof; collagen, elastin , Fibronectin, proteins selected from keratin and their derivatives and hydrolyzates; α-hydroxy acids such as glycolic acid, lactic acid, malic acid, citric acid, salicylic acid and their derivatives and their salts; serum deproteinized, spleen, Placenta, chicken crown, royal jelly, yeast, lactic acid bacteria, bifidus, reishi, carrot, senburi, rosemary, aubergine, garlic, hinokithiol, cepharanthin, aloe, salvia, arnica, chamomile, white birch, otogirisou, eucalyptus, mukuroji , Sanpens, Souhakuhi, Touki, Ibukitranoo, Clara, Sanzashi, Shirayuri, Hop, Neubara, Yokuinin, Dokudami, Seaweed, Natto, Lemongrass, Hibiscus, Ginkgo biloba extract, Phosphatidylserine and other natural products and their extracts; Adenylic acid derivatives such as triphosphate, adenosine diphosphate, adenosine monophosphate; minerals such as iron, vanadium, molybdenum, manganese, copper, potassium, magnesium, calcium, zinc, selenium, iodine; mannitol, xylitol, glucosamine Monosaccharides such as: Hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratane sulfate, glycogen, chitin, chitosan and other polysaccharides; deoxyribonucleic acid, ribonucleic acid and other nucleic acids; other glycyrrhizinic acid, guanine, mutin , Ubiquinone, α-lipoic acid, octacosanol, alicin, aliine, etc., and a mixture thereof can be selected from one or more. Preferably, vitamin A; carotenoids (excluding xanthophylls); vitamin B; vitamin C; vitamin D, vitamin E; tocotrienol; glutathione and derivatives thereof and salts thereof; catechin, anthocyanin, ellagic acid and the like. Polyphenols; linoleic acid, α- or γ-linolenic acid, arachidonic acid, eikosapentaenoic acid, sardine acid, docosahexaenoic acid and salts thereof; proteins selected from collagen, elastin, fibronectin, keratin and derivatives thereof, and Hydrolyzate; minerals such as copper and zinc; one or more can be selected from the group consisting of mutin, ubiquinone, α-lipoic acid and the like, and mixtures thereof. More preferably, vitamin A; carotenoids (excluding xanthophylls); vitamin C; vitamin E; tocotrienols; glutathione and derivatives thereof and salts thereof; polyphenols such as catechin, anthocyanin, ellagic acid; , Docosahexaenoic acid and its derivatives and salts thereof; minerals such as copper and zinc; one or more can be selected from the group consisting of mutin, ubiquinone, α-lipoic acid and the like, and mixtures thereof.

In the present invention, the lower limit of the other active ingredient is 0.1% by weight, preferably 1% by weight, more preferably 5% by weight, still more preferably 10% by weight, based on the total amount of the composition. It is 20% by weight, and the upper limit thereof is 99% by weight, preferably 90% by weight, more preferably 80% by weight, still more preferably 70% by weight, and particularly preferably 60% by weight. Further, the upper limit and the lower limit thereof can be used in combination as appropriate.
More specifically, for example, 0.1 to 99% by weight, preferably 1 to 90% by weight, more preferably 5 to 80% by weight, still more preferably 10 to 80% by weight, and particularly preferably 20 to 70% by weight. It is compounded and can be used in combination of one or more.

In the present invention, the composition of the present invention contains active ingredients and additives that can be used for foods and drinks, foods with functional claims, specified health foods, quasi-drugs, pharmaceuticals (including pharmaceuticals for mammals other than humans) and the like. It can be appropriately blended, and can be appropriately formulated by the formulation method usually used for the product.

In the present invention, foods and drinks for which improvement / prevention of symptoms is permitted are foods having medicinal effects permitted / designated by the national government or public organizations, and are, for example, foods with functional claims and foods with specified health claims. Such as health functional foods, special purpose foods, etc. Although the names and regulations change depending on the situation, the times, and the systems of each country, those that are essentially the same are included in the present invention.

In the present invention, the blending amount of the composition of the present invention is not particularly limited, and the purpose of application (type of target disease or symptom, etc.) and the target of application (human beings, animals other than humans (preferably mammals, particularly preferable). (Pets such as dogs and cats)), applicable parts, applicable gender and age, foods and drinks, foods with functional claims, specified health foods, quasi-drugs, or forms of pharmaceuticals, their administration or ingestion methods, etc. It is appropriately set according to the number of times, taste, and the like.

In the present invention, the amount of the composition of the present invention to be added to foods and drinks, foods with functional claims, specified health foods, quasi-drugs, or pharmaceuticals is not particularly limited, but the composition of the present invention per adult per day. The lower limit of the applied amount is 0.1 mg, preferably 1 mg, more preferably 10 mg, further preferably 30 mg, particularly preferably 50 mg, and the upper limit thereof is 2000 mg, preferably 1500 mg, more preferably 1000 mg, still more preferably 500 mg. , Particularly preferably 300 mg. Further, the upper limit and the lower limit thereof can be used in combination as appropriate.
More specifically, for example, it is 0.1 to 2000 mg, preferably 1 to 1500 mg, more preferably 10 to 1000 mg, still more preferably 30 to 500 mg, and particularly preferably 50 to 300 mg.

In the present invention, when the composition of the present invention is used, the lower limit of the amount of xanthophyll or a salt thereof applied per day for an adult is 0.1 mg, preferably 0.5 mg, more preferably 1 mg, still more preferably. It is 3 mg, particularly preferably 5 mg, the upper limit of which is 500 mg, preferably 250 mg, more preferably 100 mg, still more preferably 75 mg, and particularly preferably 50 mg. Further, the upper limit and the lower limit thereof can be used in combination as appropriate.
More specifically, for example, it is 0.1 to 500 mg, preferably 0.5 to 250 mg, more preferably 1 to 100 mg, still more preferably 3 to 75 mg, and particularly preferably 5 to 50 mg.

In the present invention, when the composition of the present invention is used, the lower limit of the applied amount of the processed product of the genus Trapa per adult is 0.1 mg, preferably 1 mg, more preferably 10 mg, still more preferably. It is 25 mg, particularly preferably 50 mg, the upper limit of which is 2000 mg, preferably 1500 mg, more preferably 1000 mg, still more preferably 500 mg, and particularly preferably 300 mg. Further, the upper limit and the lower limit thereof can be used in combination as appropriate.
More specifically, for example, it is 0.1 to 2000 mg, preferably 1 to 1500 mg, more preferably 10 to 1000 mg, still more preferably 25 to 500 mg, and particularly preferably 50 to 300 mg.

One aspect of the present invention is an oral or parenteral composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa. The composition of the present invention can be used as an oral composition and a parenteral composition.

One aspect of the present invention is a food or drink or pharmaceutical composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa. The composition of the present invention can be used as a food or drink and a medicine.

One aspect of the present invention is a composition for supplements containing xanthophyll or a salt thereof and a processed product of the genus Trapa. The composition of the present invention can be used as a supplement.

One aspect of the present invention is an ophthalmic composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa.

In the present invention, in addition to xanthophile and / or processed products of Trapa plants, the compositions of the present invention include other components such as excipients, thickeners, emulsifiers (eg, beeswax, glycerin fatty acid ester) and the like. Can be mixed to prepare the desired form. The form of the composition of the present invention is not particularly limited, and examples thereof include supplements such as soft capsules, hard capsules, liquids, jellies, gummies, tablets, powders, and gels.

In the present invention, when prepared as a composition for foods and drinks of the present invention, in addition to xanthophile and / or processed products of the genus Hishi, other ingredients such as sweeteners, colorants, preservatives and thickeners , Stabilizers, gelling agents, glues, antioxidants, color formers, bleaching agents, fungicides (antibacterial agents), yeast foods, gum bases, fragrances, acidulants, seasonings, emulsifiers, pH adjusters, kansui , A swelling agent, a nutrient enhancer, and other food and drink materials can be mixed to prepare a desired form. For example, the form thereof is not particularly limited, and supplement-type foods such as gels, granules, fine granules, capsules, soft capsules, tablets, powders, liquids, and semi-solids; carbonated drinks, soft drinks, etc. Beverages such as dairy drinks, alcoholic drinks, fruit juice drinks, teas and nutritional drinks; powdered drinks such as powdered juices and powdered soups; sweets such as gums, tablets, candies, cookies, gummies, senbei, biscuits and jellies; bread, It can be in the form of noodles, cereals, jams, seasonings, etc. These forms can be used, for example, as foods and drinks for preventing and / or improving visual function deterioration. For example, in addition to general foods and drinks, dietary supplements, foods with functional claims, foods for specified health use, etc. It can also be used as a nutritive for foods for the sick.

In the present invention, when prepared as a pharmaceutical composition (pharmaceutical product, quasi-drug, etc.) of the present invention, in addition to xanthophyll and / or processed products of Trapa plants, other medicinal ingredients and pharmaceuticals as necessary. It is possible to blend a carrier, an additive, etc. that are generally acceptable. For example, as a pharmaceutically acceptable carrier and additive, a binder, a disintegrant, a lubricant, a wetting agent, a buffer, a preservative, a fragrance and the like can be mixed to prepare a desired form. it can.
For example, the form thereof is not particularly limited, and injections, external preparations, inhalants, suppositories, films, troches, liquids, powders, tablets, granules, capsules, syrups, eye drops. , Eye drops, nasal drops, etc. Among these forms, a form suitable for oral administration (that is, an oral drug) is preferable, and for example, a troche agent, a liquid agent, a powder, a tablet, a granule, a capsule, a soft capsule, a syrup, or the like is particularly preferable. These forms can be used, for example, as pharmaceuticals for the prevention and / or treatment of visual impairment.

One aspect of the present invention is a composition containing xanthophyll or a salt thereof and a processed product of a Trapa plant for prevention and / or improvement of visual function deterioration and associated subjective symptoms. The composition of the present invention can be used for prevention and / or improvement of visual deterioration.

In the present invention, "decreased visual function" means that the ability to perceive visual information such as characters and images, that is, visual information such as morphology, color, lightness and darkness, and movement of an object is diminished. For example, eye fatigue. , Eye aging, or decreased eye focus adjustment function (decrease in the ability to adjust the focus on the retina by changing the thickness of the crystalline body due to contraction and relaxation of hairy muscles); Addition of senile vision, senile cataract, etc. Age-related loss of vision; includes loss of vision associated with diseases such as tired eyes, cataracts, and diabetic retinopathy. In addition, "prevention and / or improvement of visual function deterioration" means prevention or suppression, treatment or improvement of the above-mentioned visual function deterioration, and includes maintenance of visual function. Visual decline is induced, for example, by aging, UV light, poor circulation, dryness, and / or reactive oxygen species. Further, the "subsequent subjective symptom" is not particularly limited as long as it is a subjective symptom due to a decrease in visual function, and examples thereof include shoulder, nape, back or waist stiffness.

In the present invention, for a product related to the composition of the present invention, packaging of the product, information related to the product, or an advertisement related to the product (for example, transaction documents, instruction manuals, attachments, mail-order catalogs, Internet sites, etc.) Can be labeled as "prevention (or suppression) and / or improvement (or treatment) of visual deterioration", and "prevention and / or improvement of visual deterioration" is induced by, for example, ultraviolet rays. Suppression of eye damage, increase of pigment amount in the yellow spot of the eye, which decreases with aging, protection from light stimuli such as blue light, improvement of (decreased) contrast sensitivity, tone of the eye, eye Relieves fatigue, reduces eye fatigue (due to VDT work, etc.), increases the amount of pigment in the central part of the retina, protects the eyes from light stimuli (received in daily life), maintains eye health, (normal) Maintains focus adjustment function, relieves eye fatigue, relieves dry eyes, relieves deterioration of focus adjustment function, maintains visual function, maintains health of yellow spots of eyes, supports focus adjustment function , Supports contrast sensitivity (distinguishing power of color depth), maintains viewing power, helps focus adjustment function at hand, relieves the burden on the shoulders and neck muscles due to the use of eyes, etc. It is also possible to display similar to them.

One aspect of the present invention is a composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa for the prevention and / or treatment of eye diseases. The compositions of the present invention can be used for the prevention and / or treatment of eye diseases.

In the present invention, the eye disease is a disease induced by aging, ultraviolet rays, poor circulation, dryness, active oxygen and / or inflammation, and specifically, presbyopia, cataract, age-related luteal degeneration, diabetic retinopathy. Diseases, retinal pigment degeneration, central serous chorioretinopathy, glaucoma, diabetic retinopathy, presbyopia, myopia, dry eyes, winglets, inflammatory eye diseases, etc., preferably eye fatigue, cataracts, etc. Age-related cataracts, diabetic retinopathy, presbyopia, myopia, dry eyes, with presbyopia being particularly preferred.

In the present invention, the corneal disorder is not particularly limited as long as it is corneal epithelial cell death and eye diseases caused by it (dry eye, inflammatory eye disease, etc.). Preferably, it is UV-induced corneal damage, UV-induced corneal epithelial cell death and the resulting eye disease.

In the present invention, lens degeneration is a state in which a protein existing in the lens is denatured, and the cause thereof is not particularly limited. Preferably, the crystalline lens is turbid (white turbid), hardened, colored (yellowed) or changed in shape, and particularly preferably, the crystalline lens is turbid (white turbid) or hardened.

In the present invention, the eye accommodation function is not particularly limited as long as it is a function of adjusting the visual function. It is preferably a focus adjustment function, and particularly preferably a focus adjustment function in the crystalline lens.

In the present invention, the retinal choroidal disorder is an eye disease caused by damage to the retina and the damage thereof, and preferably a damage to the retina and a uveal disease caused by the damage (a disease of the retina, choroid, sclera, etc.). Is.

In the present invention, "characterized by combining xanthophyll or a salt thereof with a processed product of a Trapa plant" may mean that xanthophyll or a salt thereof and a processed product of a Trapa plant may be used in combination as each single agent. It means that it may be used as a combination drug of each component. More preferably, it is used as a compounding agent.

In the present invention, "prevention" means prevention of the onset and / or progression of each symptom or disease.

In the present invention, "treatment" means treatment of each symptom or disease.

In the present invention, "improvement" means improvement of each symptom or disease.

In the present invention, "contains ~" means "substantially contains only ~", "contains only ~", "contains ~ as an active ingredient", and "substantially contains only ~ as an active ingredient". It is also within the scope of the present invention to read "contains as" and "contains only ... as an active ingredient".

Another aspect of the present invention is an ophthalmic composition containing a processed product of a Trapa plant, and its use. For each definition of the embodiment, each definition of the composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa can be applied mutatis mutandis.

Another aspect of the present invention is a novel use of a corneal epithelial cell death inhibitor containing lutein or a salt thereof and an ophthalmic composition containing lutein or a salt thereof. For each definition of the embodiment, each definition of the composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa can be applied mutatis mutandis.

Examples of pharmacological tests are shown below, but these examples are for better understanding of the present invention and do not limit the scope of the present invention.

[Pharmacology test 1]
When the corneal epithelial cells were treated with the composition of the present invention before irradiation with ultraviolet rays (UV-B), it was evaluated whether or not the decrease in the number of living cells due to irradiation with ultraviolet rays was suppressed.

(Test method)
SV40 immortalized human corneal epithelial cells (HCE-T: Institute of Physical and Chemical Research, Bioresource Center, Cell No .: RCB2280) were seeded in 96-well plates (1 × 10 ⁴ cells / well), and SHEM medium (15% Fetal Bovine Serum) was used. 5 μg / mL Insulin, 10 ng / mL Human Epidermal Growth Factor, 40 μg / mL Genamicin-containing DMEM / F-12 medium) was cultured for 1 day.
The next day, the SHEM medium was removed, and SV40 immortalized human corneal epithelial cells were washed with PBS (Phosphate Buffered Saline).
PBS containing 0.01% (w / v) Hishi extract, PBS containing 100 μM lutein, PBS containing 0.01% (w / v) Hishi extract and 100 μM lutein, or PBS containing no test substance (control) Exchanged for.
Then, the corneal epithelial cells were ^{irradiated with 120 mJ / cm 2} UV-B (irradiation intensity: about 1 mW / cm ² , irradiation time: about 120 seconds).
After exchanging the medium of each group with DMEM / F-12 medium, culturing at 37 ° C. until the next day, using CellTiter96 (registered trademark) Aqueous One Solution Cell Proliferation Assay (manufactured by Promega, Catalog No .: G3580). The number of viable cells was measured, and the cell viability was calculated according to the following formula 1.
The Hishi extract and lutein used in this test were purchased from Hayashikane Sangyo Co., Ltd. and ChromaDex Co., Ltd., respectively.

[Equation 1]
Cell viability (%) = (number of viable cells in each group / number of viable cells in UV-B non-irradiated group) × 100

(result)
The test results are shown in FIG. In FIG. 1, the values indicate the average value ± standard error (N = 3).

(Discussion)
As is clear from FIG. 1, when the corneal epithelial cells were treated with Hishi extract alone, Lutein alone, or Hishi extract + lutein before UV-B irradiation, the cell viability was improved with respect to the control. That is, effective treatment of corneal epithelial cell death induced by UV irradiation, regardless of whether the processed product of Trapa is treated alone, xanthophyll is treated alone, or the processed product of Trapa is treated with xanthophyll in combination. It was shown that it can be suppressed. In particular, when a processed product of Trapa and xanthophyll were used in combination, it was shown that both act synergistically or complementarily to effectively suppress corneal epithelial cell death induced by ultraviolet irradiation.

[Pharmacology test 2]
It was evaluated whether or not the white turbidity (opacity) of the crystalline lens and the damage to the retina were improved when the diabetic model rat was treated with the composition of the present invention.

1. 1. Test animal (use animal)
A Wistar male rat (7 weeks old, Japan Charles River Co., Ltd. Hino Breeding Center) was brought into the breeding room of Ina Research Research Center Co., Ltd. After quarantine including acclimation for 6 days, it was used for the experiment.
During the test period, the animals were bred in the same laboratory controlled at a temperature of 23 ± 2 ° C., a humidity of 55 ± 15%, and a light-dark cycle of 12 hours (light period: 7:00 am-, dark period: 7:00 pm-). Solid feed (CRF-1, Oriental Yeast Co., Ltd., Chiba) and drinking water were allowed to be freely ingested.

2. Preparation of Diabetes Model Rats Streptozotocin (STZ) was prepared in rats at 45 mg / mL with physiological saline, 1 mL / kg was administered once intravenously in the tail vein for the first time, and STZ was 25 mg / mL with physiological saline 7 days later. As a second dose, 1 mL / kg was administered intravenously to the tail vein to induce type 1 diabetes. The same amount of physiological saline was administered to the control group (normal group). Those having a satiety blood glucose level of 250 mg / dL or more (diabetes group: DM) on the 6th day after the second STZ administration were used for the subsequent experiments.

3. 3. Experimental Protocol The DM rats described above were assigned to the following 4 groups on the 6th day after the second STZ administration so that the blood glucose levels were even.
Normal group: Water for injection 2 mL / kg / day (n = 8)
Control group: DM + water for injection 2 mL / kg / day (n = 8)
Hishi extract group: DM + 66% Hishi extract content 2 mg / kg / day (n = 8)
Lutein group: DM + lutein 20% content 2 mg / kg / day (n = 8)
Hishi extract + lutein group: DM + 66% lutein content 2 mg / kg / day + lutein 20% content 2 mg / kg / day (n = 8)
The subject administration was started the day after the allocation, and the change over time was observed for 69 days. Hishi extract is diluted with water for injection to a concentration of 1 mg / mL and 2 mL / kg / day, and lutein is diluted with safflower oil to a concentration of 1 mg / mL and 2 mL / kg / day is diluted with a polypropylene injection tube and an oral sonde for rats. Was administered orally once daily.
The cloudiness (turbidity) of the crystalline lens was evaluated on the 70th day from the start date of administration to evaluate the cloudiness (turbidity) state. The electroretinogram was measured 2 days before the start of administration of the subject and 43 days after the start of administration, a total of 2 times.
The Hishi extract and lutein used in this test were purchased from Hayashikane Sangyo Co., Ltd. and Katra Phytochem [India] Private Limited, respectively.

4. Effect on lens white turbidity (turbidity) The presence or absence of the lens cloudiness (turbidity) inhibitory effect of Hishi extract, lutein and Hishi extract + lutein was examined using diabetic model rats.
Streptozotocin (45 mg / kg, iv) was administered to Wistar rats (male, 8 weeks old) for the first time (45 mg / kg, iv), and 7 days later, the second dose (25 mg / kg, iv) was administered to induce type 1 diabetes. I let you. The Hishi extract group contains 66% Hishi extract (2 mg / kg), the lutein group contains 20% lutein (2 mg / kg), and the Hishi extract + lutein group contains 66% Hishi extract (2 mg / kg) and 20% lutein (2 mg / kg). 2 mg / kg) was orally administered once a day.
The crystalline lens was collected on the 70th day after the end of the administration period of 69 days, and the ratio of the number of completely cloudy (opaque) crystalline lenses (incidence rate of complete cloudiness) was evaluated.
The Hishi extract and lutein used in this test were purchased from Hayashikane Sangyo Co., Ltd. and Katra Phytochem [India] Private Limited, respectively.

[Equation 2]
Complete cloudiness rate (%) = (number of eyes completely clouded in each group / total number of eyes in each group) x 100

(result)
The test results are shown in FIG.

(Discussion)
As is clear from FIG. 2, all of the administration of Hishi extract alone, lutein alone, and Hishi extract + lutein suppressed the cloudiness (opacity) of the crystalline lens as compared with the control. That is, it was shown that the white turbidity (turbidity) of the crystalline lens was suppressed in both the case where the processed product of the genus Trapa was used alone, the xanthophyll was used alone, and the processed product of the genus Trapa and the xanthophyll were used in combination. ..

5. Effect on retinal damage The presence or absence of the inhibitory effect of Hishi extract, lutein and Hishi extract + lutein on retinal damage was examined using diabetic model rats.
Streptozotocin (45 mg / kg, iv) was administered to Wistar rats (male, 8 weeks old) for the first time (45 mg / kg, iv), and 7 days later, the second dose (25 mg / kg, iv) was administered to induce type 1 diabetes. I let you. The Hishi extract group contains 66% Hishi extract (2 mg / kg), the lutein group contains 20% lutein (2 mg / kg), and the Hishi extract + lutein group contains 66% Hishi extract (2 mg / kg) and 20% lutein (2 mg / kg). 2 mg / kg) was orally administered once a day.
Using the data collection / analysis system PowerLab (PowerLab system), electroretinograms (waves a and b) were measured and evaluated 2 days before the start of administration of the subject and 43 days after the start of administration.
The Hishi extract and lutein used in this test were purchased from Hayashikane Sangyo Co., Ltd. and Katra Phytochem [India] Private Limited, respectively.
Here, the electroretinogram is a potential change recorded when the retina is irradiated with light, and is used when evaluating retinal function electrophysiologically.
The basic form of this electroretinogram is classified into the first negative potential fluctuation (a wave) caused by light irradiation, and then the large positive potential fluctuation (b wave) that rises sharply and then drops sharply. The hyperpolarized phase derived from photoreceptor cells and the b-wave amplitude indicate the depolarized layer derived from Muller cells and are used to grasp the state of retinal function. That is, if any damage occurs to the retina due to various diseases or the like, the amplitude of each wave on the electroretinogram decreases.

[Equation 3]
Amplitude change rate (%) = (potential fluctuation range on the 43rd day of each group / potential fluctuation range 2 days before the start of administration) × 100

(result)
The test results are shown in FIG.

(Discussion)
As is clear from FIG. 3, when Hishi extract alone, lutein alone, and Hishi extract + lutein were administered, the decrease in the amplitude of the a wave and the b wave was suppressed or improved as compared with the control. That is, it was shown that there is a possibility of suppressing or ameliorating retinal damage when the processed product of Trapa is used alone, xanthophyll is used alone, or the processed product of Trapa and xanthophyll are used in combination. ..
[Formulation example]
Examples of the preparations are shown below, but these examples are for better understanding of the present invention and do not limit the scope of the present invention, and the present invention is limited only to these examples of preparations. It's not something.

The blending amount of each component in the pharmaceutical product example is the content per capsule in the case of soft capsules.

Pharmaceutical example 1
Hishi extract 33mg
Glycerin fatty acid ester suitable amount

Pharmaceutical example 2
Lutein 7.5mg
Hishi extract 33mg
Glycerin fatty acid ester suitable amount

Pharmaceutical example 3
Lutein 7.5mg
Hishi extract 33mg
Vitamin E 75 mg
Glycerin fatty acid ester suitable amount

Pharmaceutical example 4
Lutein 7.5mg
Hishi extract 33mg
Docosahexaenoic acid 100 mg
Glycerin fatty acid ester suitable amount

Pharmaceutical example 5
Hishi extract 33mg
Docosahexaenoic acid 100 mg
Glycerin fatty acid ester suitable amount

Pharmaceutical example 6
Lutein 7.5mg
Docosahexaenoic acid 100 mg
Glycerin fatty acid ester suitable amount

In Formulation Examples 1 to 6, a desired formulation can be formulated by appropriately adjusting the type and amount of lutein, hissi extract, and other compounding components.

The composition containing xanthophyll of the present invention or a salt thereof and a processed product of the genus Trapa can be used for prevention and / or improvement of deterioration of visual function.

Claims (41)

A composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa. The composition according to claim 1, wherein the xanthophyll is at least one selected from the group consisting of lutein, astaxanthin, β-cryptoxanthin, zeaxanthin, mesozeaxanthin, canthaxanthin, capsanthin and fucoxanthin. The composition according to claim 1 or 2, wherein the xanthophyll is at least one selected from the group consisting of lutein, astaxanthin, zeaxanthin and mesozeaxanthin. According to any one of claims 1 to 3, the processed product of Trapa japonica is a processed product of at least one Trapa plant selected from the group consisting of Trapa incisa, Trapa incisa, Trapa japonica, Trapa natans and Trapa natans. The composition described. The composition according to any one of claims 1 to 4, wherein the processed product of the genus Trapa is a pulverized product and / or an extract of the peel of the genus Trapa. The composition according to any one of claims 1 to 5, wherein the processed product of the genus Trapa contains 0.1 to 80% by weight of polyphenol with respect to the total weight of the processed product of the genus Trapa. A composition containing lutein or a salt thereof and a processed product of Tobishi. The composition according to claim 7, wherein the processed product of Tobishi is a pulverized product and / or extract of the peel of Tobishi. The composition according to claim 7 or 8, wherein the processed Tobishi product contains 0.1 to 80% by weight of polyphenol based on the total weight of the processed Tobishi product. The composition according to any one of claims 1 to 9, wherein the composition is for oral or parenteral use. The composition according to any one of claims 1 to 10, wherein the composition is for food or drink or pharmaceutical use. The composition according to any one of claims 1 to 11, wherein the composition is for a supplement. The composition according to any one of claims 1 to 12, wherein the composition is for ophthalmology. The composition according to any one of claims 1 to 13, wherein the composition is a soft capsule, a hard capsule, a liquid preparation, a jelly, a gummies, a tablet or a powder. The composition according to any one of claims 1 to 14, for preventing and / or ameliorating visual dysfunction and associated subjective symptoms. The composition according to claim 15, wherein the decrease in visual function is eye fatigue, aging of the eye, or decrease in the ability to adjust the focus of the eye. The composition according to claim 15 or 16, wherein the visual dysfunction is a visual dysfunction induced by aging, ultraviolet rays, poor circulation, dryness, reactive oxygen species and / or inflammation. The composition according to claim 15, wherein the subjective symptom is stiff shoulders, nape of the neck, back or lower back. The composition according to claims 1 to 14, for the prevention and / or treatment of eye diseases. The composition according to claim 19, wherein the eye disease is an eye disease induced by aging, ultraviolet rays, poor circulation, dryness, active oxygen and / or inflammation. Eye diseases include asthenopia, cataract, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, central serous chorioretinopathy, glaucoma, glaucoma, presbyopia, myopia, dry eye and inflammatory eye diseases The composition according to claim 19 or 20, which is selected from the group consisting of. The composition according to any one of claims 1 to 14, for the prevention, amelioration and / or treatment of corneal disorders. The composition according to claim 22, wherein the corneal disorder is an ultraviolet-induced corneal disorder. The composition according to any one of claims 1 to 14, for the prevention, amelioration and / or treatment of lens degeneration. 24. The composition of claim 24, wherein the lens denaturation is opacity or hardening of the lens. The composition according to any one of claims 1 to 14, for the prevention, improvement and / or treatment of deterioration of accommodation function. The composition according to claim 26, wherein the eye accommodation function is an accommodation accommodation function. The composition according to any one of claims 1 to 14, for the prevention, amelioration and / or treatment of retinochoroidal disorders. 28. The composition of claim 28, wherein the retinal choroidal disorder is damage to the retina. An agent for preventing and / or ameliorating visual dysfunction and associated subjective symptoms, which is characterized by combining xanthophyll or a salt thereof with a processed product of the genus Trapa. A prophylactic and / or therapeutic agent for eye diseases, which comprises combining xanthophyll or a salt thereof with a processed product of the genus Trapa. A prophylactic, ameliorating and / or therapeutic agent for corneal disorders, which comprises combining xanthophyll or a salt thereof with a processed product of the genus Trapa. A prophylactic, ameliorating and / or therapeutic agent for lens degeneration, which comprises combining xanthophyll or a salt thereof with a processed product of the genus Trapa. A prophylactic, ameliorating and / or therapeutic agent for the deterioration of accommodation function, which is characterized by combining xanthophyll or a salt thereof with a processed product of the genus Trapa. A prophylactic, ameliorating and / or therapeutic agent for reticulochoroidal disorders, which comprises combining xanthophyll or a salt thereof with a processed product of the genus Trapa. An ophthalmic composition containing a processed product of the genus Trapa. The ophthalmic composition according to claim 36, for preventing and / or ameliorating visual dysfunction and associated subjective symptoms. The ophthalmic composition according to claim 36, for the prevention and / or treatment of eye diseases. The ophthalmic composition according to claim 36, for the prevention, amelioration and / or treatment of corneal disorders. The ophthalmic composition according to claim 36, for the prevention, amelioration and / or treatment of lens degeneration. The ophthalmic composition according to claim 36, for the prevention, amelioration and / or treatment of retinochoroidal disorders.

Images